Bayer's Strategic Gamble: Betting on Pharma Amid Legal and Financial Headwinds

Bayer's stock surged 101% as its drug Kerendia booms, but a Supreme Court case on glyphosate and €5B in 2026 litigation costs pose major risks.

The German conglomerate Bayer is navigating a critical period, with its pharmaceutical division showing robust growth while significant legal and financial challenges loom. The company's stock, which closed the previous week at €40.12, has surged approximately 101% over the past twelve months, reflecting a complex investor calculus weighing operational promise against persistent risks.

A major focal point for investors is the United States Supreme Court. Oral arguments in the case Durnell v. Monsanto are scheduled for April 27, 2026, with a ruling expected by June. The case centers on whether federal law preempts state-level liability claims regarding glyphosate warning labels. CEO Bill Anderson has framed the Court's decision to hear the case as a crucial step toward achieving regulatory clarity for the industry. A favorable outcome could substantially reduce the company's litigation liabilities, which are backed by provisions of €11.8 billion. For 2026 alone, management anticipates litigation-related cash outflows of around €5 billion, primarily tied to glyphosat.

Financially, the company is under pressure. Net financial debt stood at nearly €29.9 billion at the end of 2025, while free cash flow fell by almost one-third to €2.08 billion. Despite this, Bayer has confirmed its full-year 2026 outlook, targeting an EBITDA before special items of €9.6 to €10.1 billion and currency-adjusted sales of €45 to €47 billion. Pharma COO Sebastian Guth recently told Reuters that new US import tariffs on pharmaceuticals do not alter this forecast, citing an existing trade agreement that caps duties on most goods, including medicines, at 15%.

The pharmaceutical business is providing the core growth narrative. The drug Kerendia, for chronic kidney disease in diabetes, is its standout performer. It posted a sales jump of almost 93% in the fourth quarter of 2025 to €264 million, reaching €829 million for the full year. On a currency- and portfolio-adjusted basis, recent growth was 88%. Management has set a long-term peak sales target exceeding €3 billion for the drug. This ambition received a boost in late March when the European Commission granted an expanded approval for Kerendia to treat heart failure in adults, opening access to millions of additional patients in Europe.

Looking beyond Kerendia, Bayer aims to return to mid-single-digit sales growth from 2027 onward and lift its operating margin to around 30% by 2030. Its pipeline candidates in oncology, cardiology, neurology, and immunology are intended to drive this. Early clinical data for the prostate cancer candidate 225Ac-PSMA-Trillium showed an overall response rate of 46% with no treatment-related deaths, a result noted as remarkable for this early stage. To better capitalize on its US portfolio, Bayer will establish a new leadership structure for its US pharmaceuticals market effective May 1, 2026.

Corporate governance is also in focus. At the virtual Annual Stockholders' Meeting on April 24, shareholders will vote on proposed supervisory board changes, with Marcel Smits and Alfred Stern slated to replace Paul Achleitner and Colleen Goggins. The company has proposed an unchanged dividend of €0.11 per share, with payment scheduled for April 29.

Analyst sentiment remains supportive of the stock's recovery. Goldman Sachs maintains a buy rating with a price target of €54.50, while JPMorgan confirms an "Overweight" rating and a €50.00 target, praising the company's solid operational foundation. The immediate trading week begins a quiet period ahead of quarterly results, setting the stage for a consequential fortnight defined by the Annual Meeting and the Supreme Court hearing. The coming weeks will test whether the pharmaceutical division's momentum can sustainably counterbalance the weight of debt and litigation.